
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1435817
This article is part of the Research Topic Case Reports in Autoimmune and Autoinflammatory Disorders View all 42 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Involvement of the intestinal autonomic nerves in Guillain-Barré syndrome (GBS) can lead to paralytic ileus, a condition commonly observed in severe cases during later stages of the disease. Cases with paralytic ileus as a presenting symptom are very rare. We report a case of a 35-year-old male patient who was admitted to the hospital with acute abdominal pain persisting for 12 hours. Abdominal CT suggested small bowel obstruction, for which routine conventional pharmacological treatment were ineffective. Subsequently, the patient presented with multiple sets of cranial nerve paralysis, bilateral symmetrical delayed paralysis, distal limb numbness, respiratory failure, urinary retention, shock, and electrophysiology, suggesting axonal-type multifocal peripheral nerve damage. Notably, blood antiganglioside tests showed IgG positivity for anti-sulfatide antibodies, anti-GD1a antibodies, and anti-GT1a antibodies. The patient was administered plasma exchange combined with intravenous immunoglobulin, and symptoms gradually improved. The patient resumed independent ambulation within two months and returned to normal status at one year, with no recurrence of symptoms. Given that paralytic ileus can precede other neurological abnormalities in patients with GBS, early detection and individualized treatment are critical to reduce the risk of death and promote recovery. Here, we demonstrate that intensive immunotherapy is a viable therapeutic approach that can be clinically adopted for such conditions.
Keywords: Ileus, Guillain-Barré syndrome, intensive immunotherapy, case report, GBS
Received: 21 May 2024; Accepted: 12 Mar 2025.
Copyright: © 2025 Luo, Chen, Li, Deng, Chen, Chen, Liu, Zhang and Zhu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ling Zhu, Xiangtan Central Hospital, Xiangtan, Hunan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.